Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Anna Cetnarowska *Functional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0002-0539-3152
Mette Hyldahl *Functional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0002-7407-6062
Marcus NygårdFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0009-0002-1762-8593
Hesam DashtiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Bo Vagner HansenFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0001-9468-2839
Laura Kristine HolmFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.
Kaja MadsenFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0002-2647-6715
Maria Stahl MadsenFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0002-5039-340X
Vallari ShuklaFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0003-3329-5418
Esra Durmaz MitchellFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0002-4345-2264
Alexander RauchFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0002-9429-7356
Jesper Grud Skat MadsenFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark.ORCID http://orcid.org/0000-0002-0518-0800
Susanne MandrupFunctional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Science, University of Southern Denmark, Odense M, Denmark. s.mandrup@bmb.sdu.dk.ORCID http://orcid.org/0000-0002-0961-5787
Funding
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M
Bridging the gap between type 2 diabetes GWAS and therapeutic targetsUM1DK126185 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLAUSSNITZER, MELINA C, GLOYN, ANNA LOUISE · 2020 to 2024
$9.5M
Danmarks Grundforskningsfond (Danish National Research Foundation) 141EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 860002Lundbeckfonden (Lundbeck Foundation) R218-2016-1450Natur og Univers, Det Frie Forskningsråd (Natural Sciences, Danish Council for Independent Research) 12-125524NIDDK NIH HHS P30 DK040561Novo Nordisk Fonden (Novo Nordisk Foundation) NNF18OC0033444Novo Nordisk Fonden (Novo Nordisk Foundation) NNF21OC0071613Novo Nordisk Fonden (Novo Nordisk Foundation) NNF21SA0072102U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) UM1DK126185
6 · The paper itself
Abstract
Transcriptional master regulators drive cell fate transitions. Peroxisome proliferator-activated receptor γ (PPARγ) is the master regulator of adipogenesis, and its expression must therefore be tightly regulated and efficiently induced in response to adipogenic cues. Here we decipher the regulatory mechanisms of the highly connected enhancer community driving activation of the PPARG locus during adipocyte differentiation of human mesenchymal stem cells. By systematically deleting nine individual enhancers, spanning upstream, promoter-proximal, and downstream super-enhancer constituents, we demonstrate elaborate enhancer crosstalk in cis involving stabilization of C/EBPβ recruitment prior to chromatin remodeling. We show that the super-enhancer constituent E + 102 plays a dual role in cis crosstalk and feedback activation and is obligate for activation of PPARG expression. Non-coding genetic variants associated with cardiometabolic traits and predicted to regulate PPARG expression map to E + 102 and other essential enhancers in the community, thereby supporting the importance of these enhancers in human physiology and disease.
Indexed as
AdipogenesisEnhancer Elements, GeneticPPAR gammaAdipocytesCCAAT-Enhancer-Binding Protein-betaCell DifferentiationChromatin Assembly and DisassemblyGene Expression RegulationHumansMesenchymal Stem CellsPromoter Regions, GeneticSuper EnhancersCCAAT-Enhancer-Binding Protein-betaPPAR gammaPPARG protein, human
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Extensive enhancer crosstalk controls PPARG2 activation during adipogenesis. · full record | OpenQuestion